Association of lymph node metastases, grade and extent of mesenteric lymph node dissection in locoregional small intestinal neuroendocrine tumors with recurrence‐free survival

• Published in: Journal of neuroendocrinology 2022-11, Vol.34 (11), p.e13205-n/a
• Main Authors: Daskalakis, Kosmas, Wedin, Maria, Tsoli, Marina, Kogut, Angelika, Srirajaskanthan, Raj, Sarras, Konstantinos, Kattiparambil, Sajith, Giovos, George, Weickert, Martin O., Kos‐Kudla, Beata, Kaltsas, Gregory
• Format: Article
• Language: English
• Subjects: Aged; Female; Humans; Intestine; Ki-67 Antigen; Ki-67 proliferation index; locoregional resective surgery; Lymph Node Excision; lymph node metastases; Lymph nodes; Lymph Nodes - surgery; Lymphatic Metastasis; Lymphatic system; Male; Medical prognosis; Metastases; Metastasis; Middle Aged; Neuroendocrine tumors; Neuroendocrine Tumors - surgery; Original; Patients; recurrence; small intestinal neuroendocrine tumors; Survival; Translational and Clinical Neuroendocrinology
• ISSN: 0953-8194; 1365-2826; 1365-2826
• DOI: 10.1111/jne.13205

We aimed to assess the prognostic impact of tumor‐ and patient‐related parameters in patients with stage I–III small intestinal neuroendocrine tumors (SI‐NETs), who underwent locoregional resective surgery (LRS) with curative intent. We included 229 patients with stage I–III SI‐NETs diagnosed from June 15, 1993, through March 8, 2021, identified using the SI‐NET databases from five European referral centers. Mean ± SD age at baseline was 62.5 ± 13.6 years; 111/229 patients were women (49.3%). All tumors were well‐differentiated; 160 were grade 1 (G1) tumors, 51 were G2, two were G3 and 18 tumors were of unspecified grade (median Ki‐67: 2%, range 1%–50%). One‐hundred and sixty‐three patients (71.2%) had lymph node (LN) involvement. The median number of retrieved lymph nodes was 10 (0–63), whereas the median number of positive LNs was 2 (0–43). After a mean ± SD follow‐up of 54.1 ± 64.1 months, 60 patients experienced disease recurrence at a median (range) of 36.2 (2.5–285.1) months. The 5‐ and 10‐year recurrence‐free survival (RFS) rates were 66.6% and 49.3% respectively. In univariable analysis, there was no difference in RFS and overall survival (OS) between LN‐positive and LN‐negative patients (log‐rank, p = .380 and .198, respectively). However, in stage IIIb patients who underwent mesenteric lymph node dissection (MLND) with a minimum of five retrieved LN (n = 125), five or more LN metastases were associated with shorter RFS (median RFS [95% CI] = 107.4 [0–229.6] vs. 73.7 [35.3–112.1] months; log‐rank, p = .048). In addition, patients with G2 tumors exhibited shorter RFS compared to patients with G1 tumors (median RFS [95% confidence interval (CI)] = 46.9 [36.4–57.3] vs. 120.7 [82.7–158.8] months; log‐rank, p = .001). In multivariable Cox‐regression RFS analysis in stage IIIb patients, the Ki‐67 proliferation index (hazard ratio = 1.08, 95% CI = 1.035–1.131; p